Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
Rémi Marty1, Stéphane Roze1, Hannah Kurth21HEVA, Lyon, 2IPSEN, Boulogne-Billancourt, FranceBackground: Long-acting somatostatin receptor ligands (SRL) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and...
Main Authors: | Marty R, Roze S, Kurth H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-05-01
|
Series: | Medical Devices : Evidence and Research |
Online Access: | http://www.dovepress.com/decision-tree-model-for-health-economic-comparison-of-two-long-acting--a9789 |
Similar Items
-
Novel Somatostatin Receptor Ligands Therapies for Acromegaly
by: Rosa Maria Paragliola, et al.
Published: (2018-03-01) -
Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
by: Joan Gil, et al.
Published: (2021-03-01) -
Prescription patterns of long-acting somatostatin analogues
by: Jorge Enrique Machado-Alba, et al.
Published: (2017-03-01) -
Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
by: Adelman DT, et al.
Published: (2012-12-01) -
Internalisation of somatostatin agonists and somatostatin{sub2} receptor
by: Frawley, Lisa Antoinette
Published: (2002)